- Home
- HVT vs MNPR Comparison
HVT vs MNPR Comparison
Compare HVT & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HVT
- MNPR
- Stock Information
- Founded
- HVT 1885
- MNPR 2014
- Country
- HVT United States
- MNPR United States
- Employees
- HVT N/A
- MNPR N/A
- Industry
- HVT Other Specialty Stores
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- HVT Consumer Discretionary
- MNPR Health Care
- Exchange
- HVT Nasdaq
- MNPR Nasdaq
- Market Cap
- HVT 290.0M
- MNPR 249.5M
- IPO Year
- HVT N/A
- MNPR 2019
- Fundamental
- Price
- HVT $20.28
- MNPR $31.44
- Analyst Decision
- HVT
- MNPR Strong Buy
- Analyst Count
- HVT 0
- MNPR 5
- Target Price
- HVT N/A
- MNPR $59.50
- AVG Volume (30 Days)
- HVT 125.0K
- MNPR 18.2K
- Earning Date
- HVT 04-30-2025
- MNPR 05-13-2025
- Dividend Yield
- HVT 6.11%
- MNPR N/A
- EPS Growth
- HVT N/A
- MNPR N/A
- EPS
- HVT 1.28
- MNPR N/A
- Revenue
- HVT $720,469,000.00
- MNPR N/A
- Revenue This Year
- HVT $4.96
- MNPR N/A
- Revenue Next Year
- HVT $8.28
- MNPR N/A
- P/E Ratio
- HVT $16.36
- MNPR N/A
- Revenue Growth
- HVT N/A
- MNPR N/A
- 52 Week Low
- HVT $17.01
- MNPR $1.72
- 52 Week High
- HVT $29.85
- MNPR $54.30
- Technical
- Relative Strength Index (RSI)
- HVT 51.81
- MNPR 37.28
- Support Level
- HVT $19.94
- MNPR $28.40
- Resistance Level
- HVT $21.15
- MNPR $36.82
- Average True Range (ATR)
- HVT 0.50
- MNPR 3.13
- MACD
- HVT -0.03
- MNPR -0.68
- Stochastic Oscillator
- HVT 30.99
- MNPR 27.91
About HVT Haverty Furniture Companies Inc.
Haverty Furniture Companies Inc is a specialty retailer of residential furniture and accessories. It provides various products such as Sofa Tables, Sleepers, End Tables, Cocktail Tables, Accent Pieces, Display Cabinets, Wall Decor, floral and Tress, and other related products. The company operates in the Southern and Midwestern U.S. All its activities are encompassed in its Merchandise division. The company derives the majority of its revenue from its upholstery products and, secondarily, from bedroom furniture.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.